A novel B. megaterium/ω-3 PUFA synbiotic formulation modulated the inflammatory response in ulcerative colitis biopsies, reducing pro-inflammatory cytokines and promoting a macrophage profile associated with resolution of inflammation.
Key Findings
Background
Fermentation of ω-3 PUFA lysine salt with Bacillus megaterium DSM 32963 produced a synbiotic formulation with enhanced anti-inflammatory and pro-resolving activity compared to unfermented ω-3 PUFAs.
The study specifically used Bacillus megaterium DSM 32963 as the fermenting organism
The substrate was ω-3 PUFA lysine salt, not standard free-form ω-3 PUFAs
Fermentation was hypothesized to enhance conversion of ω-3 PUFAs into specialized pro-resolving mediators (SPMs)
The rationale was that limited physiological conversion of ω-3 PUFAs into SPMs may explain inconsistent clinical responses in IBD
Results
The B. megaterium/ω-3 PUFA synbiotic formulation reduced the expression of selected pro-inflammatory cytokines in ex vivo ulcerative colitis colon biopsies.
Inflammatory cytokine expression was assessed using qPCR and Western blotting
Biopsies were obtained from patients with ulcerative colitis (UC) and healthy subjects
The reduction in pro-inflammatory cytokine expression was observed in UC biopsies treated ex vivo with the formulation
Specific cytokines targeted were described as 'selected pro-inflammatory cytokines'
Results
The synbiotic formulation promoted a macrophage profile associated with resolution of inflammation in ulcerative colitis colon tissue.
Macrophage-associated markers were assessed using qPCR, Western blotting, and immunofluorescence
The formulation promoted what the authors describe as a 'pro-resolving macrophage profile'
This effect was observed in ex vivo colon biopsies from UC patients
The shift in macrophage profile was identified as a key mechanistic finding supporting pro-resolving activity of the formulation
Results
The study provides preliminary evidence that microbial conversion of ω-3 PUFAs can enhance their pro-resolving activity in human colonic tissue.
The evidence was described by the authors as 'preliminary' given the ex vivo study design
The study used human colonic tissue directly, increasing translational relevance
Biopsies from both UC patients and healthy subjects were included for comparison
The authors concluded that 'further in vivo and clinical investigations are required'
Conclusions
The B. megaterium/ω-3 PUFA synbiotic approach was identified as a potentially promising nutritional adjunct for ulcerative colitis management.
The formulation is described as a 'synbiotic' combining a probiotic bacterium (B. megaterium) and a prebiotic/functional substrate (ω-3 PUFA lysine salt)
The approach was framed as a nutritional adjunct, not a replacement for existing therapies
Clinical responses to standard ω-3 PUFA supplementation in IBD were noted to remain inconsistent, motivating this approach
The authors called for further in vivo and clinical investigations before clinical application
What This Means
This research suggests that combining a specific bacterium (Bacillus megaterium) with omega-3 fatty acids through a fermentation process creates a new type of 'synbiotic' supplement with stronger anti-inflammatory properties than omega-3s alone. The scientists tested this formulation on colon tissue samples taken directly from patients with ulcerative colitis — a chronic inflammatory bowel disease — and found that it reduced the levels of inflammation-promoting proteins and shifted immune cells called macrophages into a state associated with resolving rather than promoting inflammation. The key idea is that the bacterium may help convert omega-3 fatty acids into more potent, specialized molecules that the body uses to actively switch off inflammation, a process that is often inefficient on its own.
The study addresses a well-known puzzle in nutritional medicine: while omega-3 fatty acids (found in fish oil) show promise for inflammatory bowel disease in laboratory settings, results in human clinical trials have been mixed. This research suggests one reason may be that the body does not efficiently convert standard omega-3 supplements into the specialized anti-inflammatory compounds it needs, and that microbial fermentation could bridge that gap. By examining actual human colon tissue from UC patients rather than cell lines or animal models, the findings are considered more directly relevant to human disease.
However, the authors themselves describe these findings as 'preliminary' since the experiments were conducted on tissue samples outside the body (ex vivo) rather than in living patients. They emphasize that further animal studies and human clinical trials are needed before conclusions can be drawn about effectiveness or safety as a treatment. This research represents an early but potentially meaningful step toward developing more effective nutritional strategies for people with ulcerative colitis.
Check Your Own Numbers
Upload your bloodwork. We'll cross-reference your results against this study and 4,700 others.